US intergroup anal carcinoma trial

Tumor diameter predicts for colostomy

Jaffer A. Ajani, Kathryn A. Winter, Leonard L. Gunderson, John Pedersen, Al B. Benson, Charles R. Thomas, Robert J. Mayer, Michael Haddock, Tyvin A. Rich, Christopher G. Willett

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Purpose The US Gastrointestinal Intergroup Radiation Therapy Oncology Group 98-11 anal carcinoma trial showed that cisplatin-based concurrent chemoradiotherapy resulted in a significantly higher rate of colostomy compared with mitomycin-based therapy. Established prognostic variables for patients with anal carcinoma include tumor diameter, clinical nodal status, and sex, but pretreatment variables that would predict the likelihood of colostomy are unknown. Methods A secondary analysis was performed by combining patients in the two treatment arms to evaluate whether new predictive and prognostic variables would emerge. Univariate and multivariate analyses were carried out to correlate overall survival (OS), disease-free survival, and time to colostomy (TTC) with pretreatment and treatment variables. Results Of 682 patients enrolled, 644 patients were assessable and analyzed. In the multivariate analysis, tumor-related prognosticators for poorer OS included node-positive cancer (P ≤.0001), large (> 5 cm) tumor diameter (P =.01), and male sex (P =.016). In the treatment-related categories, cisplatin-based therapy was statistically significantly associated with a higher rate of colostomy (P =.03) than was mitomycin-based therapy. In the pretreatment variables category, only large tumor diameter independently predicted for TTC (P =.008). Similarly, the cumulative 5-year colostomy rate was statistically significantly higher for large tumor diameter than for small tumor diameter (Gray's test; P =.0074). Clinical nodal status and sex were not predictive of TTC. Conclusion The combined analysis of the two arms of RTOG 98-11, representing the largest prospective database, reveals that tumor diameter (irrespective of the nodal status) is the only independent pretreatment variable that predicts TTC and 5-year colostomy rate in patients with anal carcinoma.

Original languageEnglish (US)
Pages (from-to)1116-1121
Number of pages6
JournalJournal of Clinical Oncology
Volume27
Issue number7
DOIs
StatePublished - Mar 1 2009
Externally publishedYes

Fingerprint

Colostomy
Carcinoma
Neoplasms
Mitomycin
Cisplatin
Therapeutics
Multivariate Analysis
Radiation Oncology
Survival
Chemoradiotherapy
Disease-Free Survival
Radiotherapy
Databases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., Thomas, C. R., ... Willett, C. G. (2009). US intergroup anal carcinoma trial: Tumor diameter predicts for colostomy. Journal of Clinical Oncology, 27(7), 1116-1121. https://doi.org/10.1200/JCO.2008.19.6857

US intergroup anal carcinoma trial : Tumor diameter predicts for colostomy. / Ajani, Jaffer A.; Winter, Kathryn A.; Gunderson, Leonard L.; Pedersen, John; Benson, Al B.; Thomas, Charles R.; Mayer, Robert J.; Haddock, Michael; Rich, Tyvin A.; Willett, Christopher G.

In: Journal of Clinical Oncology, Vol. 27, No. 7, 01.03.2009, p. 1116-1121.

Research output: Contribution to journalArticle

Ajani, JA, Winter, KA, Gunderson, LL, Pedersen, J, Benson, AB, Thomas, CR, Mayer, RJ, Haddock, M, Rich, TA & Willett, CG 2009, 'US intergroup anal carcinoma trial: Tumor diameter predicts for colostomy', Journal of Clinical Oncology, vol. 27, no. 7, pp. 1116-1121. https://doi.org/10.1200/JCO.2008.19.6857
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR et al. US intergroup anal carcinoma trial: Tumor diameter predicts for colostomy. Journal of Clinical Oncology. 2009 Mar 1;27(7):1116-1121. https://doi.org/10.1200/JCO.2008.19.6857
Ajani, Jaffer A. ; Winter, Kathryn A. ; Gunderson, Leonard L. ; Pedersen, John ; Benson, Al B. ; Thomas, Charles R. ; Mayer, Robert J. ; Haddock, Michael ; Rich, Tyvin A. ; Willett, Christopher G. / US intergroup anal carcinoma trial : Tumor diameter predicts for colostomy. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 7. pp. 1116-1121.
@article{8fc40f0fe363498595cb925bc3ca380e,
title = "US intergroup anal carcinoma trial: Tumor diameter predicts for colostomy",
abstract = "Purpose The US Gastrointestinal Intergroup Radiation Therapy Oncology Group 98-11 anal carcinoma trial showed that cisplatin-based concurrent chemoradiotherapy resulted in a significantly higher rate of colostomy compared with mitomycin-based therapy. Established prognostic variables for patients with anal carcinoma include tumor diameter, clinical nodal status, and sex, but pretreatment variables that would predict the likelihood of colostomy are unknown. Methods A secondary analysis was performed by combining patients in the two treatment arms to evaluate whether new predictive and prognostic variables would emerge. Univariate and multivariate analyses were carried out to correlate overall survival (OS), disease-free survival, and time to colostomy (TTC) with pretreatment and treatment variables. Results Of 682 patients enrolled, 644 patients were assessable and analyzed. In the multivariate analysis, tumor-related prognosticators for poorer OS included node-positive cancer (P ≤.0001), large (> 5 cm) tumor diameter (P =.01), and male sex (P =.016). In the treatment-related categories, cisplatin-based therapy was statistically significantly associated with a higher rate of colostomy (P =.03) than was mitomycin-based therapy. In the pretreatment variables category, only large tumor diameter independently predicted for TTC (P =.008). Similarly, the cumulative 5-year colostomy rate was statistically significantly higher for large tumor diameter than for small tumor diameter (Gray's test; P =.0074). Clinical nodal status and sex were not predictive of TTC. Conclusion The combined analysis of the two arms of RTOG 98-11, representing the largest prospective database, reveals that tumor diameter (irrespective of the nodal status) is the only independent pretreatment variable that predicts TTC and 5-year colostomy rate in patients with anal carcinoma.",
author = "Ajani, {Jaffer A.} and Winter, {Kathryn A.} and Gunderson, {Leonard L.} and John Pedersen and Benson, {Al B.} and Thomas, {Charles R.} and Mayer, {Robert J.} and Michael Haddock and Rich, {Tyvin A.} and Willett, {Christopher G.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1200/JCO.2008.19.6857",
language = "English (US)",
volume = "27",
pages = "1116--1121",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - US intergroup anal carcinoma trial

T2 - Tumor diameter predicts for colostomy

AU - Ajani, Jaffer A.

AU - Winter, Kathryn A.

AU - Gunderson, Leonard L.

AU - Pedersen, John

AU - Benson, Al B.

AU - Thomas, Charles R.

AU - Mayer, Robert J.

AU - Haddock, Michael

AU - Rich, Tyvin A.

AU - Willett, Christopher G.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Purpose The US Gastrointestinal Intergroup Radiation Therapy Oncology Group 98-11 anal carcinoma trial showed that cisplatin-based concurrent chemoradiotherapy resulted in a significantly higher rate of colostomy compared with mitomycin-based therapy. Established prognostic variables for patients with anal carcinoma include tumor diameter, clinical nodal status, and sex, but pretreatment variables that would predict the likelihood of colostomy are unknown. Methods A secondary analysis was performed by combining patients in the two treatment arms to evaluate whether new predictive and prognostic variables would emerge. Univariate and multivariate analyses were carried out to correlate overall survival (OS), disease-free survival, and time to colostomy (TTC) with pretreatment and treatment variables. Results Of 682 patients enrolled, 644 patients were assessable and analyzed. In the multivariate analysis, tumor-related prognosticators for poorer OS included node-positive cancer (P ≤.0001), large (> 5 cm) tumor diameter (P =.01), and male sex (P =.016). In the treatment-related categories, cisplatin-based therapy was statistically significantly associated with a higher rate of colostomy (P =.03) than was mitomycin-based therapy. In the pretreatment variables category, only large tumor diameter independently predicted for TTC (P =.008). Similarly, the cumulative 5-year colostomy rate was statistically significantly higher for large tumor diameter than for small tumor diameter (Gray's test; P =.0074). Clinical nodal status and sex were not predictive of TTC. Conclusion The combined analysis of the two arms of RTOG 98-11, representing the largest prospective database, reveals that tumor diameter (irrespective of the nodal status) is the only independent pretreatment variable that predicts TTC and 5-year colostomy rate in patients with anal carcinoma.

AB - Purpose The US Gastrointestinal Intergroup Radiation Therapy Oncology Group 98-11 anal carcinoma trial showed that cisplatin-based concurrent chemoradiotherapy resulted in a significantly higher rate of colostomy compared with mitomycin-based therapy. Established prognostic variables for patients with anal carcinoma include tumor diameter, clinical nodal status, and sex, but pretreatment variables that would predict the likelihood of colostomy are unknown. Methods A secondary analysis was performed by combining patients in the two treatment arms to evaluate whether new predictive and prognostic variables would emerge. Univariate and multivariate analyses were carried out to correlate overall survival (OS), disease-free survival, and time to colostomy (TTC) with pretreatment and treatment variables. Results Of 682 patients enrolled, 644 patients were assessable and analyzed. In the multivariate analysis, tumor-related prognosticators for poorer OS included node-positive cancer (P ≤.0001), large (> 5 cm) tumor diameter (P =.01), and male sex (P =.016). In the treatment-related categories, cisplatin-based therapy was statistically significantly associated with a higher rate of colostomy (P =.03) than was mitomycin-based therapy. In the pretreatment variables category, only large tumor diameter independently predicted for TTC (P =.008). Similarly, the cumulative 5-year colostomy rate was statistically significantly higher for large tumor diameter than for small tumor diameter (Gray's test; P =.0074). Clinical nodal status and sex were not predictive of TTC. Conclusion The combined analysis of the two arms of RTOG 98-11, representing the largest prospective database, reveals that tumor diameter (irrespective of the nodal status) is the only independent pretreatment variable that predicts TTC and 5-year colostomy rate in patients with anal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=61449252531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449252531&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.19.6857

DO - 10.1200/JCO.2008.19.6857

M3 - Article

VL - 27

SP - 1116

EP - 1121

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -